NDATRANSDERMALGEL, METERED
Approved
Dec 2006
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
6/8 — Strong
ELESTRIN (estradiol) by Viatris (2) is estrogen receptor agonists [moa]. Approved for menopause, postmenopausal vaginal atrophy, atrophic vaginitis and 4 more indications. First approved in 2006.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ELESTRIN is a transdermal gel formulation of estradiol, an estrogen receptor agonist approved in 2006 for menopausal symptoms and postmenopausal vaginal atrophy. It works by activating estrogen receptors to replace declining hormone levels and address estrogen-deficiency symptoms. The product has a broad off-label indication profile spanning contraception, metabolic disorders, and psychiatric conditions.
$0.179MPart D
LOE ApproachingNiche product with minimal claims volume and approaching loss of exclusivity, indicating a small, consolidating brand team focused on retention rather than growth.
Mechanism of Action
Estrogen Receptor Agonists
Pharmacologic Class:
Estrogen
Indications (7)
Worked on ELESTRIN at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.